We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
- Authors
Cohen, Steven J; Zalupski, Mark M; Modiano, Manuel R; Conkling, Paul; Patt, Yehuda Z; Davis, Peg; Dorr, Robert T; Boytim, Michelle L; Hersh, Evan M
- Abstract
Imexon is an aziridine-derived iminopyrrolidone which has synergy with gemcitabine in pancreatic cancer cell lines. Gemcitabine is a standard therapy for pancreatic cancer. We performed a phase I trial of imexon and gemcitabine to evaluate safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) in patients with advanced pancreatic cancer.
- Publication
Cancer chemotherapy and pharmacology, 2010, Vol 66, Issue 2, p287
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-009-1162-y